Cetrorelix Evidence Guide
Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine.
Our Take
Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine.
- Evidence context
- IVF ovarian stimulation protocols, LH surge prevention, GnRH antagonist research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.25mg subcutaneous daily (starting stimulation day 5 or 6) or 3mg single-dose protocol
Benefits and Evidence
- Premature LH Surge Prevention (IVF): Level A, includes human evidence - Effectively prevents premature ovulation during IVF stimulation. Meta-analyses show comparable pregnancy rates to GnRH agonist long protocols with shorter treatment duration and fewer injections.
- Reduced OHSS Risk: Level A, includes human evidence - GnRH antagonist protocols are associated with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to agonist protocols, as they allow GnRH agonist triggering instead of hCG.
- Rapid Gonadotropin Suppression: Level A, includes human evidence - Produces significant LH suppression within 8 hours and near-complete suppression within 24 hours. Faster onset than any GnRH agonist protocol.
Side Effects and Warnings
- Injection site reactions (redness, swelling)
- Headache
- Nausea
- OHSS (lower incidence than agonist protocols)
- Ovarian enlargement
- Not for use in women with severe renal impairment
- Hypersensitivity reactions including anaphylaxis have been reported
- Must be used under supervision of fertility specialist
Research Dosage References
- <strong>Subcutaneous</strong> - 0.25 mg daily - Daily starting day 5-7 of ovarian stimulation until trigger day - Standard IVF flexible protocol. Initiation based on follicle size or fixed day of stimulation. Continue until hCG or GnRH agonist trigger.
- <strong>Subcutaneous</strong> - 3 mg single dose - Single injection on stimulation day 7 - Single-dose protocol. If trigger not given within 4 days, add 0.25 mg daily until trigger. Less commonly used than daily protocol.
Mechanism of Action
Cetrorelix acts as a competitive GnRH receptor antagonist: 1. Competitive receptor blockade: Occupies the GnRH receptor without activating it, preventing endogenous GnRH from binding and triggering gonadotropin release. 2. Immediate suppression: Unlike agonists, there is no initial stimulatory phase. LH and FSH levels decline within hours of administration. 3. Dose-dependent duration: Single 3 mg dose provides suppression for approximately 4 days; daily 0.25 mg doses provide continuous suppression. 4. Rapid reversibility: Upon discontinuation, pituitary function recovers within 1-2 days as the drug is cleared and endogenous GnRH can again access receptors.
Legal Status
FDA-approved prescription medication (Cetrotide). Prescription only. Not a controlled substance.
Primary Sources
- GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis. Human Reproduction Update, 2016.
- Cetrorelix for preventing premature LH surges in women undergoing ovarian stimulation. Human Reproduction, 1997.
Quick Answers
Where is the strongest evidence for Cetrorelix?
Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine. Evidence context: IVF ovarian stimulation protocols, LH surge prevention, GnRH antagonist research.
What are the main side effects of Cetrorelix?
Cetrorelix side effects and warning signals include Injection site reactions (redness, swelling), Headache, Nausea, OHSS (lower incidence than agonist protocols), and Ovarian enlargement.
What evidence level is Cetrorelix?
Cetrorelix is rated Level A; the listed research status is FDA Approved.